AbCellera Biologics Inc. (ABCL): Total Liabilities
$390.05M
As of 2025-12-31
$411.56M
As of 2026-06-30
+8.2%
3-year compound annual growth
+17.4%
5-year compound annual growth
| Period ended | Total Liabilities | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $390.05M | +28.1% | 2026-02-24, Balance as of period end |
| 2024-12-31 | $304.47M | -9.3% | 2026-02-24, Balance as of period end |
| 2023-12-31 | $335.78M | +9.1% | 2025-02-27, Balance as of period end |
| 2022-12-31 | $307.63M | +5.1% | 2024-02-20, Balance as of period end |
| 2021-12-31 | $292.84M | +67.3% | 2023-02-21, Balance as of period end |
| 2020-12-31 | $175.03M | n/a | 2022-02-25, Balance as of period end |
Total Liabilities at similar companies
| Company | Year ended | Total Liabilities | Change YoY |
|---|---|---|---|
| AbCellera Biologics Inc. (ABCL) | 2025-12-31 | $390.05M | +28.1% |
| CytomX Therapeutics, Inc. (CTMX) | 2025-12-31 | $52.56M | -56.6% |
| Bicycle Therapeutics PLC (BCYC) | 2025-12-31 | $107.62M | -34.3% |
| Assembly Biosciences, Inc. (ASMB) | 2025-12-31 | $50.84M | -40.8% |
| Viridian Therapeutics, Inc. (VRDN) | 2025-12-31 | $177.25M | +150.5% |
| Eton Pharmaceuticals, Inc. (ETON) | 2025-12-31 | $65.96M | +27.6% |
| ADC Therapeutics SA (ADCT) | 2025-12-31 | $508.98M | -3.0% |
| Rockwell Medical, Inc. (RMTI) | 2025-12-31 | $20.16M | -24.3% |
| Arcturus Therapeutics Holdings Inc. (ARCT) | 2025-12-31 | $57.16M | -44.6% |
Compare ABCL, CTMX, BCYC, ASMB side by side · Screen every company in Pharmaceutical Preparations ↗